OBJECTIVE: To examine the associations between hormonal contraceptive use and measures of HIV disease progression and antiretroviral treatment (ART) effectiveness. STUDY DESIGN: A prospective cohort study of women with prevalent HIV infection in St. Petersburg, Russia, was conducted. After contraceptive counseling, participants chose to use combined oral contraceptives (COCs), depot-medroxyprogesterone acetate (DMPA), a copper intrauterine device (IUD) or male condoms for pregnancy prevention. Among participants not using ART at enrollment, we used multivariate Cox regression to assess the association between current (time-varying) contraceptive use and disease progression, measured by the primary composite outcome of CD4 decline to <350 cells/mm(3), ART initiation or death. Among participants using ART at enrollment, we used linear mixed models to estimate the predicted mean CD4 change at select time points by contraceptive method. RESULTS: During a total of 5233 months follow-up among participants not using ART with enrollment CD4 ≥350 cells/mm(3) (n=315), 97 experienced disease progression. Neither current use of COCs [adjusted hazard ratio (aHR) 0.91, 95% confidence interval (CI) 0.56-1.48] nor DMPA (aHR 1.28, 95% CI 0.71-2.31) was associated with a statistically significant increased risk for disease progression compared with use of nonhormonal methods (IUD or condoms). Among participants using ART at enrollment (n=77), we found no statistically significant differences in the predicted mean changes in CD4 cell count comparing current use of COCs (p=.1) or DMPA (p=.3) with nonhormonal methods. CONCLUSION: Hormonal contraceptive use was not significantly associated with measures of HIV disease progression or ART effectiveness among women with prevalent HIV infection. IMPLICATIONS: Hormonal contraceptive use was not significantly associated with measures of HIV disease progression or ART effectiveness among women with prevalent HIV infection. Published by Elsevier Inc.
OBJECTIVE: To examine the associations between hormonal contraceptive use and measures of HIV disease progression and antiretroviral treatment (ART) effectiveness. STUDY DESIGN: A prospective cohort study of women with prevalent HIV infection in St. Petersburg, Russia, was conducted. After contraceptive counseling, participants chose to use combined oral contraceptives (COCs), depot-medroxyprogesterone acetate (DMPA), a copper intrauterine device (IUD) or male condoms for pregnancy prevention. Among participants not using ART at enrollment, we used multivariate Cox regression to assess the association between current (time-varying) contraceptive use and disease progression, measured by the primary composite outcome of CD4 decline to <350 cells/mm(3), ART initiation or death. Among participants using ART at enrollment, we used linear mixed models to estimate the predicted mean CD4 change at select time points by contraceptive method. RESULTS: During a total of 5233 months follow-up among participants not using ART with enrollment CD4 ≥350 cells/mm(3) (n=315), 97 experienced disease progression. Neither current use of COCs [adjusted hazard ratio (aHR) 0.91, 95% confidence interval (CI) 0.56-1.48] nor DMPA (aHR 1.28, 95% CI 0.71-2.31) was associated with a statistically significant increased risk for disease progression compared with use of nonhormonal methods (IUD or condoms). Among participants using ART at enrollment (n=77), we found no statistically significant differences in the predicted mean changes in CD4 cell count comparing current use of COCs (p=.1) or DMPA (p=.3) with nonhormonal methods. CONCLUSION: Hormonal contraceptive use was not significantly associated with measures of HIV disease progression or ART effectiveness among women with prevalent HIV infection. IMPLICATIONS: Hormonal contraceptive use was not significantly associated with measures of HIV disease progression or ART effectiveness among women with prevalent HIV infection. Published by Elsevier Inc.
Entities:
Keywords:
Antiretroviral agents/therapeutic use; CD4 lymphocyte count; Contraceptive agents; Female/administration and dosage/adverse effects; HIV seropositivity/complications/drug therapy/mortality
Authors: Chelsea B Polis; Maria J Wawer; Noah Kiwanuka; Oliver Laeyendecker; Joseph Kagaayi; Tom Lutalo; Fred Nalugoda; Godfrey Kigozi; David Serwadda; Ronald H Gray Journal: AIDS Date: 2010-07-31 Impact factor: 4.177
Authors: P H Kilmarx; K Limpakarnjanarat; J Kaewkungwal; R Srismith; S Saisorn; W Uthaivoravit; N L Young; T D Mastro Journal: J Infect Dis Date: 2000-05-08 Impact factor: 5.226
Authors: Chelsea B Polis; Gertrude Nakigozi; Victor Ssempijja; Fredrick E Makumbi; Iga Boaz; Steven J Reynolds; Anthony Ndyanabo; Tom Lutalo; Maria J Wawer; Ronald H Gray Journal: Contraception Date: 2012-06-18 Impact factor: 3.375
Authors: Helen E Cejtin; Lisa Jacobson; Gayle Springer; D Heather Watts; Alexandra Levine; Ruth Greenblatt; Kathryn Anastos; Howard L Minkoff; Leslie S Massad; Julie B Schmidt Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: Mardge H Cohen; Audrey L French; Lorie Benning; Andrea Kovacs; Kathryn Anastos; Mary Young; Howard Minkoff; Nancy A Hessol Journal: Am J Med Date: 2002-08-01 Impact factor: 4.965
Authors: Ludo Lavreys; Jared M Baeten; Joan K Kreiss; Barbra A Richardson; Bhavna H Chohan; Wisal Hassan; Dana D Panteleeff; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh Journal: J Infect Dis Date: 2004-01-09 Impact factor: 5.226
Authors: David Hubacher; Jennifer Liku; James Kiarie; Joel Rakwar; Peter Muiruri; Jackline Omwenga; Pai-Lien Chen Journal: J Int AIDS Soc Date: 2013-03-01 Impact factor: 5.396
Authors: Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones Journal: Contraception Date: 2018-02-09 Impact factor: 3.375
Authors: Kavita Nanda; Gretchen S Stuart; Jennifer Robinson; Andrew L Gray; Naomi K Tepper; Mary E Gaffield Journal: AIDS Date: 2017-04-24 Impact factor: 4.177